

Remarks

By this amendment, new claims 133-137 have been added to the application. The application includes claims 34-36 and 98-137.

New claim 133 is directed to a composition comprising recombinant or synthetic APR-1 antigen, an adjuvant, and a pharmacologically acceptable carrier. Support for this new claim is found in the specification in Example 14, on page 112, at lines 1-3, and on page 22, at line 8.

New claim 134 directed to the composition of claim 98 which comprises the antigen APR-1 and an adjuvant. Support for this new claim is found in the specification, for example, in Example 14, on page 112, at lines 1-3 and on page 22, line 8. Further, APR-1 is listed as a potential antigen for this composition in the list of antigens in claim 101, which depends from claim 98.

New claim 135 is directed to the method of claim 103 (method of eliciting an immune response in a mammal) in which the recombinant or synthetic antigen in the composition is APR-1, and the composition further comprises an adjuvant. Support for this new claim is found in the specification, for example, in Example 14, on page 112, at lines 1-3, and on page 22 at line 8. Further, APR-1 is listed as a potential antigen for this composition in the list of antigens in claim 107, which depends from claim 103.

New claim 136 recites the method of claim 110 (for reducing blood loss in a patient infected with hookworm) by administering a composition comprising recombinant or synthetic antigen APR-1, and further comprising an adjuvant. Support for this claim can be found in the specification at, for example, in Example 14, on page 112, at lines 1-3 and on page 22 at line 8. Further, APR-1 is listed as a potential antigen for this composition in the list of antigens in claim 114, which depends from claim 110.

New claim 137 recites the method of claim 117 (reducing hookworm size, quantitative egg count, or hookworm burden) by administering a composition comprising recombinant or synthetic antigen comprising APR-1 and an adjuvant. Support for this new claim is found in the specification, for example, in Example 14 at page 121, lines 12-13 and lines 18-19, and on page 22 at line 8. Further, APR-1 is listed as a potential antigen for this composition in the list of antigens in claim 121, which depends from claim 117.

Applicant submits that these new claims thus do not go beyond the disclosure of the application.


Formal Matters and Conclusion

The Examiner is respectfully requested to examine and pass the above application to issue at the earliest possible time.

Should the Examiner find the application to be other than in condition for allowance, the Examiner is requested to contact the undersigned at the local telephone number listed below to discuss any other changes deemed necessary in a telephonic or personal interview.

Please charge any underpayment or credit any overpayment of fees to attorney's deposit account #50-2041.

Respectfully submitted,



Ruth E. Tyler-Cross

Reg. No. 45,922

Whitham, Curtis & Christofferson
11491 Sunset Hills Road; Suite 340
Reston, VA 20190
703-787-9400